Scott R. Smith
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Scott R. Smith has a total of 7 co-authors. Here are the top co-authors by number of shared publications:
Carol E. Golin
Department of Medicine, School of Medicine, and Assistant Professor, Department of Health Behavior and Health Education, School of Public Health, UNC
1 shared publicationCheryl Marcus
School of Medicine, University of North Carolina at Chapel Hill, AIDS Clinical Trials Unit, 211A West Cameron Avenue, Campus Box #7215, Chapel Hill, NC 27599-7215, USA
1 shared publicationDuane M. Kirking
1 shared publicationJohn C Rublein
Department of Pharmacy, University of North Carolina Hospitals, 101 Manning Drive, Campus Box #7600, Chapel Hill, NC 27514, USA
1 shared publicationMargaret A Chesney
School of Medicine, University of California at San Francisco, UCSF AIDS Research Institute, 74 New Montgomery Street, Suite 600, San Francisco, CA 94105-3444, USA
1 shared publicationSusan Reif
Center for Health Policy, Law, and Management, Duke University, Durham, NC
1 shared publication
Latest Publications
- Open Access
- 1 June 2004
- Published by Oxford University Press (OUP) in American Journal of Health-System Pharmacy
- Vol. 61 (11) , 1120-1129
Influence of time stress and other variables on counseling by pharmacists about antiretroviral medications
Purpose: The medication counseling practices of pharmacists caring for patients with HIV infection and the factors influencing their counseling behaviors regarding antiretroviral medications were examined. Methods: A questionnaire was mailed in February 2000 to pharmacist-managers of 573 ambulatory care pharmacies providing medications to beneficiaries of the North Carolina AIDS Drug Assistance Program. The frequency of and attitudes about adherence counseling for patients with HIV infection; the time allocated, spent, and needed to provide high-quality care to these patients; and pharmacists' time pressure and time stress were measured. Results: Of the 573 questionnaires mailed, 440 (77%) were usable. Fifty-nine percent of pharmacists reported that they did not have enough time to provide adherence counseling to patients receiving antiretroviral medications, and 45% reported that most of their patients did not receive such counseling. Time-stressed pharmacists were significantly less likely to perform 12 of 22 counseling behaviors, including discussing adverse effects (13% versus 24%, p < 0.0089), drug interactions (13% versus 31%, p < 0.0001), and what to do if a dose is missed (8% versus 23%, p < 0.0001). Multivariate analysis revealed that time stress, perceived skill and interest in adherence counseling, and job satisfaction were significantly associated with the counseling index. Conclusion: Time pressure and other barriers appeared to limit the care that some pharmacists offered to patients with HIV infection. Pharmacist age, job satisfaction, and perceived skill and interest in adherence counseling influenced the comprehensiveness of the counseling pharmacists provided for patients receiving antiretroviral medications.
- 1 June 2004
- Published by Oxford University Press (OUP) in American Journal of Health-System Pharmacy
- Vol. 61 (11) , 1120-1129
Open AccessInfluence of time stress and other variables on counseling by pharmacists about antiretroviral medications
Purpose: The medication counseling practices of pharmacists caring for patients with HIV infection and the factors influencing their counseling behaviors regarding antiretroviral medications were examined. Methods: A questionnaire was mailed in February 2000 to pharmacist-managers of 573 ambulatory care pharmacies providing medications to beneficiaries of the North Carolina AIDS Drug Assistance Program. The frequency of and attitudes about adherence counseling for patients with HIV infection; the time allocated, spent, and needed to provide high-quality care to these patients; and pharmacists' time pressure and time stress were measured. Results: Of the 573 questionnaires mailed, 440 (77%) were usable. Fifty-nine percent of pharmacists reported that they did not have enough time to provide adherence counseling to patients receiving antiretroviral medications, and 45% reported that most of their patients did not receive such counseling. Time-stressed pharmacists were significantly less likely to perform 12 of 22 counseling behaviors, including discussing adverse effects (13% versus 24%, p < 0.0089), drug interactions (13% versus 31%, p < 0.0001), and what to do if a dose is missed (8% versus 23%, p < 0.0001). Multivariate analysis revealed that time stress, perceived skill and interest in adherence counseling, and job satisfaction were significantly associated with the counseling index. Conclusion: Time pressure and other barriers appeared to limit the care that some pharmacists offered to patients with HIV infection. Pharmacist age, job satisfaction, and perceived skill and interest in adherence counseling influenced the comprehensiveness of the counseling pharmacists provided for patients receiving antiretroviral medications.
- 1 June 2003
- Published by Elsevier in Patient Education and Counseling
- Vol. 50 (2) , 187-199
A medication self-management program to improve adherence to HIV therapy regimens
- 1 June 2003
- Published by Elsevier in Patient Education and Counseling
- Vol. 50 (2) , 187-199
A medication self-management program to improve adherence to HIV therapy regimens
- 1 September 2002
- Published by Elsevier in The Lancet
- Vol. 360 (9336) , 816
Multinational economic evaluations of pharmaceuticals
- 1 September 2002
- Published by Elsevier in The Lancet
- Vol. 360 (9336) , 816
Multinational economic evaluations of pharmaceuticals
- 1 October 2001
- Published by Wolters Kluwer Health in JAIDS Journal of Acquired Immune Deficiency Syndromes
- Vol. 28 (2) , 140-149
The Effect of Insurance Coverage Changes on Drug Utilization in HIV Disease
Background:Insurance coverage facilitates access to life-saving medications for many patients with HIV disease. Thus, the effects of insurance coverage changes, such as the gain or loss of coverage, may be important in explaining patient access and adherence to the medications used in the treatment of HIV disease. Objectives:The study's objective was to examine whether changes in health insurance coverage affect rates of prescription drug use by patients with HIV disease. Methods:Data were ascertained from adults participating in a series of up to six interviews as part of the AIDS Costs and Services Utilization Survey (ACSUS). ACSUS was an 18-month panel survey of patients in care for HIV/AIDS at 26 sites located in 10 U.S. cities. Poisson regression analyses with generalized estimating equations were conducted to determine the effects of demographic and socioeconomic variables on the acquisition rate of antiretrovirals, antipneumocystics, and antidepressants. The analytic sample consisted of 1566 respondents who provided 6518 interviews. Results:Although changes in insurance coverage were common, complete loss of insurance was reported in only 1.5% of the interviews whereas gaining insurance was reported in 3.3% of interviews. Having no coverage was associated with significantly lower rates of antiretroviral (rate ratio [RR], 0.73), antipneumocystic (RR, 0.58) and antidepressant use (RR, 0.31). Gaining insurance coverage was associated with lower antiretroviral (RR, 0.75) and antipneumocystic (RR, 0.70) use whereas losing insurance was associated with lower antiretroviral use (RR, 0.58). In multivariate analyses, these associations remained. Conclusions:Changes in health insurance coverage are associated with lower rates of drug use for some medications used by patients with HIV disease. Address correspondence and reprint requests to Scott R. Smith, Division of Pharmaceutical Policy and Evaluative Sciences, 205 Beard Hall, Campus Box #7360, Chapel Hill, NC 27599-7360 U.S.A.; e-mail: [email protected] Manuscript received July 31, 2000; accepted June 28, 2001. © 2001 Lippincott Williams & Wilkins, Inc.
- 1 October 2001
- Published by Wolters Kluwer Health in JAIDS Journal of Acquired Immune Deficiency Syndromes
- Vol. 28 (2) , 140-149
The Effect of Insurance Coverage Changes on Drug Utilization in HIV Disease
Background:Insurance coverage facilitates access to life-saving medications for many patients with HIV disease. Thus, the effects of insurance coverage changes, such as the gain or loss of coverage, may be important in explaining patient access and adherence to the medications used in the treatment of HIV disease. Objectives:The study's objective was to examine whether changes in health insurance coverage affect rates of prescription drug use by patients with HIV disease. Methods:Data were ascertained from adults participating in a series of up to six interviews as part of the AIDS Costs and Services Utilization Survey (ACSUS). ACSUS was an 18-month panel survey of patients in care for HIV/AIDS at 26 sites located in 10 U.S. cities. Poisson regression analyses with generalized estimating equations were conducted to determine the effects of demographic and socioeconomic variables on the acquisition rate of antiretrovirals, antipneumocystics, and antidepressants. The analytic sample consisted of 1566 respondents who provided 6518 interviews. Results:Although changes in insurance coverage were common, complete loss of insurance was reported in only 1.5% of the interviews whereas gaining insurance was reported in 3.3% of interviews. Having no coverage was associated with significantly lower rates of antiretroviral (rate ratio [RR], 0.73), antipneumocystic (RR, 0.58) and antidepressant use (RR, 0.31). Gaining insurance coverage was associated with lower antiretroviral (RR, 0.75) and antipneumocystic (RR, 0.70) use whereas losing insurance was associated with lower antiretroviral use (RR, 0.58). In multivariate analyses, these associations remained. Conclusions:Changes in health insurance coverage are associated with lower rates of drug use for some medications used by patients with HIV disease. Address correspondence and reprint requests to Scott R. Smith, Division of Pharmaceutical Policy and Evaluative Sciences, 205 Beard Hall, Campus Box #7360, Chapel Hill, NC 27599-7360 U.S.A.; e-mail: [email protected] Manuscript received July 31, 2000; accepted June 28, 2001. © 2001 Lippincott Williams & Wilkins, Inc.